Vascular endothelial growth factor (VEGF) in autoimmune diseases.
about
Neuroantibody biomarkers: links and challenges in environmental neurodegeneration and autoimmunitySU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulationThe defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia.Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis.Posterior reversible encephalopathy syndrome in a postpartum hemorrhagic woman without hypertension: A case report.Vascular pathology in multiple sclerosis: mind boosting or myth busting?Spectral imaging reveals microvessel physiology and function from anastomoses to thromboses.Development and experimental test of support vector machines virtual screening method for searching Src inhibitors from large compound libraries.Assessment of microalbuminuria for early diagnosis and risk prediction in dengue infections.Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis.TLR-4 and VEGF polymorphisms in chronic periaortitisPlasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases.Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases.Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid ArthritisSerum Level of Vascular Endothelial Growth Factor in Patients with Different Clinical SubtypeS of Oral Lichen Planus.Pathway analysis of seven common diseases assessed by genome-wide association.Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGFTumor gangliosides accelerate murine tumor angiogenesis.Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis.Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis.Angiogenic activity in sera of patients with systemic lupus erythematosus.Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus.Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.Changes of serum growth factors profiles in patients with venous thromboembolism.Serum Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Disease Activity in Lupus Nephritis.Expression of vascular endothelial growth factor and other cytokines in atopic dermatitis, and correlation with clinical features.Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers.Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome
P2860
Q27010245-6EADBD58-BC5C-4B82-B942-87B0E07D6B5AQ28483604-E9CDC74B-FCA1-42F8-AB37-59BBCCD9C9BEQ33416398-468C8827-0E87-4D5F-B9E2-E19C1D95B0C2Q33432575-AE4B2B4A-76F8-4558-BE3C-AC84B652DB07Q33606272-2B33F29D-02D3-4AFF-BEFB-5417972DE56EQ33960741-5A2239DC-9221-45D8-9394-403AE17405B2Q34049847-5A4859BA-7E71-4407-8591-AE7A56934DD2Q34485998-E1E197A4-903F-4D7B-B304-9003DCECE0F5Q34563259-BCB62280-2CCF-425B-93F7-0EB9F0681813Q34700316-2A8D4DD5-B0F4-463B-BE80-82CA43AC310AQ34729825-9034F47D-AA09-4E1A-BEAD-76952D9E39A4Q35949808-6A786CA6-D6E3-4E4A-96E6-F76E6FDE2AA7Q36095767-A1D8D638-6C9D-46DC-815F-58D69953F1C1Q36101506-3901940F-F28A-492B-856F-8BA6CFBD1D29Q36589688-3B0C9D4D-6DC3-4835-A8EF-9E89E8B26F86Q37014849-C472E71D-8B6F-4925-B4AE-5355E8BE188DQ37293884-CA597D64-5BC1-4087-98AC-7A7FD9EEA47DQ37732501-1A411CE2-F43F-46FA-A0BD-B6B2AA35881EQ38501724-552BC39E-E2C7-4F49-A0AA-80C9C59288B9Q39303280-33EACE97-043A-4AE4-8FAB-1B9DB84BD4CAQ39423164-4D31570B-22FF-4C20-BC7D-46CAFDF6D83DQ39986140-D31A937A-1636-47F7-ACC5-717A71BE6FE5Q41139248-AF9273AC-3C5B-4904-88DA-70EBAD894B63Q43184381-7C0FFAB0-22E4-4277-BD57-B869CB1DBB06Q48287759-31DAE673-0F25-4627-ACEB-01B247BA14F6Q49476251-BACB2606-5F25-43C9-9CAE-F3F2FE53DD9BQ50279952-9D4B5E08-23D0-4E15-9A09-301F10BEC632Q54648845-F2BDD238-8A62-4225-8163-995BD3AAC43BQ58776694-7A3C07E5-D708-45AA-92D5-E26B1F597931
P2860
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
@en
type
label
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
@en
prefLabel
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
@en
P1476
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
@en
P2093
Jozélio Freire Carvalho
P2888
P304
P356
10.1007/S10875-007-9083-1
P577
2007-03-06T00:00:00Z